Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zeyin Rong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-1834-1864; OpenAlex author ID A5034729834. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 10

  1. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.05.012↗
  2. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  3. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  4. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  5. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  6. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  7. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. First author DOI 10.3390/ijms24043476↗
  8. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/bib/bbab388↗
  9. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  10. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. Co-author DOI 10.7150/thno.56174↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 9 shared papers, 2021–2026 · strength 1.73
  2. Zhen Tan · 7 shared papers, 2021–2026 · strength 1.33
  3. Qingcai Meng · 7 shared papers, 2021–2026 · strength 1.32
  4. Jin Xu · 7 shared papers, 2021–2026 · strength 1.23
  5. Chen Liang · 6 shared papers, 2021–2026 · strength 1.20
  6. Si Shi · 7 shared papers, 2021–2026 · strength 1.19
  7. Jie Hua · 6 shared papers, 2021–2026 · strength 1.10
  8. Wei Wang · 5 shared papers, 2021–2026 · strength 0.96
  9. Rong Tang · 4 shared papers, 2022–2026 · strength 0.81
  10. Jianhui Yang · 3 shared papers, 2025–2026 · strength 0.72
  11. Qiong Du · 3 shared papers, 2025–2026 · strength 0.64
  12. Mingming Xiao · 2 shared papers, 2025 · strength 0.41
  13. Jin Xu · 2 shared papers, 2025 · strength 0.41
  14. Jin Xu · 1 shared paper, 2026 · strength 0.27
  15. Miaoyan Wei · 1 shared paper, 2026 · strength 0.27
  16. Jiaoshun Chen · 1 shared paper, 2026 · strength 0.23
  17. Haoyu Wang · 1 shared paper, 2026 · strength 0.23
  18. Chen Chen · 1 shared paper, 2026 · strength 0.23
  19. Liquan Jin · 1 shared paper, 2026 · strength 0.23
  20. Heng Zhu · 1 shared paper, 2025 · strength 0.22
  21. Xiaomeng Liu · 1 shared paper, 2025 · strength 0.22
  22. Xu He · 1 shared paper, 2025 · strength 0.22
  23. Rong Tang · 1 shared paper, 2025 · strength 0.19
  24. Yingna Liao · 1 shared paper, 2025 · strength 0.19
  25. Wei Wang · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.